Loading...

Debt And Patent Expiries Will Erode US Pharma Margins

Published
09 Apr 25
Updated
07 May 25
AnalystLowTarget's Fair Value
US$35.86
22.2% overvalued intrinsic discount
10 Sep
US$43.83
Loading
1Y
-15.6%
7D
0.5%

Author's Valuation

US$35.8622.2% overvalued intrinsic discount

AnalystLowTarget Fair Value

Shared on07 May 25
Fair value Decreased 27%

Shared on30 Apr 25
Fair value Decreased 3.70%

AnalystLowTarget made no meaningful changes to valuation assumptions.

Shared on16 Apr 25
Fair value Increased 26%

AnalystLowTarget made no meaningful changes to valuation assumptions.